ALLMedicine™ Hemochromatosis Center
Research & Reviews 929 results
https://doi.org/10.1124/jpet.122.001435
The Journal of Pharmacology and Experimental Therapeutics; Cutts AJ, Chowdhury S et. al.
Mar 24th, 2023 - Divalent metal transporter 1 (DMT1) cotransports ferrous iron and protons and is the primary mechanism for uptake of nonheme iron by enterocytes. Inhibitors are potentially useful as therapeutic agents to treat iron overload disorders such as here...
https://doi.org/10.1182/blood.2022016779
Blood Bennett C, Jackson VE et. al.
Mar 18th, 2023 - Polycythemia Vera (PV) is a myeloproliferative neoplasm driven by activating mutations in JAK2 that result in unrestrained erythrocyte production, increasing patients' hematocrit and hemoglobin concentration, placing them at risk of life-threateni...
https://doi.org/10.1097/MPH.0000000000002639
Journal of Pediatric Hematology/oncology; Imashuku S, Suemori SI et. al.
Mar 11th, 2023 - Differential diagnosis of juvenile hemochromatosis along with hemolytic anemia is often difficult. We report a 23-year-old woman with macrocytic hemolytic anemia with iron overload. The patient showed high serum ferritin and transferrin saturation...
https://emedicine.medscape.com/article/149684-overview
Mar 10th, 2023 - Background Percutaneous liver biopsy is a procedure in which a long needle is introduced through the skin, subcutaneous tissues, intercostal muscles, and peritoneum into the liver to obtain a specimen of liver tissue. [1, 2] This procedure is usua...
https://emedicine.medscape.com/article/149684-print
Mar 10th, 2023 - Background Percutaneous liver biopsy is a procedure in which a long needle is introduced through the skin, subcutaneous tissues, intercostal muscles, and peritoneum into the liver to obtain a specimen of liver tissue.[1, 2] This procedure is usual...
Guidelines 5 results
https://doi.org/10.14309/ajg.0000000000000315
The American Journal of Gastroenterology; Kowdley KV, Brown KE et. al.
Jul 25th, 2019 - Hereditary hemochromatosis (HH) is one of the most common genetic disorders among persons of northern European descent. There have been recent advances in the diagnosis, management, and treatment of HH. The availability of molecular diagnostic tes...
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.
Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929861
European Journal of Human Genetics : EJHG; Porto G, Brissot P et. al.
Jul 15th, 2015 - Molecular genetic testing for hereditary hemochromatosis (HH) is recognized as a reference test to confirm the diagnosis of suspected HH or to predict its risk. The vast majority (typically >90%) of patients with clinically characterized HH are ho...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125
Hepatology (Baltimore, Md.); Bacon BR, Adams PC et. al.
Apr 1st, 2011 - Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.|2011|Bacon BR,Adams PC,Kowdley KV,Powell LW,Tavill AS,|blood,diagnosis,physiopathology,therapy,metabolism,pathology,m...
https://doi.org/10.1016/j.jhep.2010.03.001
Journal of Hepatology;
May 18th, 2010 - Iron overload in humans is associated with a variety of genetic and acquired conditions. Of these, HFE hemochromatosis (HFE-HC) is by far the most frequent and most well-defined inherited cause when considering epidemiological aspects and risks fo...
Drugs 41 results see all →
Clinicaltrials.gov 72 results
https://clinicaltrials.gov/ct2/show/NCT03323346
Mar 8th, 2023 - Inclusion criteria: Patients with stage IV breast cancer with metastases demonstrated by appropriate imaging techniques Histologically or cytologically confirmed tumor Age of 18 years or more Eastern Cooperative Oncology Group (ECOG) performance s...
https://clinicaltrials.gov/ct2/show/NCT00001971
Mar 6th, 2023 - Study Description: This is a clinical research protocol to allow for collection of samples and data obtained during clinical evaluation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to cre...
https://clinicaltrials.gov/ct2/show/NCT05742035
Feb 23rd, 2023 - Iron overload in hereditary hemochromatosis is treated by phlebotomy. In Switzerland and in many other coutries, these individuals are not accepted for blood donation until ferritin values and phlebotomy intervals are in the normal range. Individu...
https://clinicaltrials.gov/ct2/show/NCT04770870
Feb 14th, 2023 - The Hintermann Series H3® (H3) prosthesis is a mobile bearing total ankle replacement (TAR) indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis or arth...
https://clinicaltrials.gov/ct2/show/NCT00068159
Feb 8th, 2023 - Hereditary hemochromatosis (HH) is the most common hereditary metabolic abnormality among Caucasians. Homozygosity for the Cys282Tyr mutation, which is the most common known mutation with a predisposition to iron overload, occurs with an estimated...
News 93 results
https://www.mdedge.com/dermatology/article/259165/hair-nails/iron-screening-alopecia-areata-patients-may-catch-hereditary
Bonnie Leung, BSc, Linsey Lindley, MD, PhD et. al.
Nov 2nd, 2022 - The role of micronutrients in the hair follicle cycle is not fully understood; thus deficiency and/or excess of certain micronutrients may be a modifiable risk factor associated with the development and/or treatment of some types of hair loss and.
https://www.medscape.com/viewarticle/981152
Sep 21st, 2022 - Patients with iron overload — serum ferritin > 1000 µg/L or a diagnosis of hemochromatosis or thalassemia — were 60% more likely to have an osteoporotic fracture during an up to 10-year follow-up than matched control patients, in a large study. Co...
https://www.onclive.com/view/american-oncology-network-physicians-research-is-well-represented-at-the-ash-annual-meeting-exposition
Dec 23rd, 2021 - American Oncology Network, LLC (AON) is pleased to announce that eight research studies co-authored by AON physicians were presented at the American Society of Hematology (ASH) Annual Meeting & Exposition, held December 11-14, 2021. Abstracts sub...
https://www.onclive.com/view/fda-lifts-hold-on-rusfertide-clinical-development-program
Oct 12th, 2021 - The FDA has removed the full clinical hold that had previously been placed on trials evaluating rusfertide (PTG-300), according to an announcement from Protagonist Therapeutics, Inc.1 With this decision, dosing on all studies evaluating the agent ...
https://www.onclive.com/view/dr-fitzgerald-on-minimizing-use-of-chemotherapy-in-breast-cancer
Oct 6th, 2021 - Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial, which found that for intermediate-risk women wit...